Amyloidosis Clinical Trials

150 recruitingLast updated: July 17, 2026

There are 150 actively recruiting amyloidosis clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Pavia, Italy. Updated daily from ClinicalTrials.gov.


Amyloidosis Trials at a Glance

150 actively recruiting trials for amyloidosis are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 26 trials, with the heaviest enrollment activity in Boston, New York, and Pavia. Lead sponsors running amyloidosis studies include Fondazione IRCCS Policlinico San Matteo di Pavia, Alnylam Pharmaceuticals, and Mayo Clinic.

Browse amyloidosis trials by phase

Treatments under study

About Amyloidosis Clinical Trials

Looking for clinical trials for Amyloidosis? There are currently 34 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Amyloidosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Amyloidosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 150 trials

Recruiting
Phase 2

Teclistamab-Daratumumab in AL Amyloidosis

Amyloid Light-chain Amyloidosis
Rajshekhar Chakraborty, MD25 enrolled3 locationsNCT07110844
Recruiting

Hungarian National Systemic Amyloidosis Registry

AL AmyloidosisAmyloid CardiomyopathyATTR Amyloidosis+1 more
Semmelweis University300 enrolled12 locationsNCT07689331
Recruiting
Not Applicable

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL AmyloidosisAmyloidosis; Systemic
Jin Lu, MD41 enrolled7 locationsNCT06192979
Recruiting
Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

AmyloidosisLight Chain AmyloidosisRelapsed AL Amyloidosis+1 more
Alexion Pharmaceuticals, Inc.91 enrolled18 locationsNCT07081646
Recruiting
Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

CardiomyopathiesAmyloidosisHeart Diseases+3 more
Eidos Therapeutics, a BridgeBio company587 enrolled103 locationsNCT06563895
Recruiting

Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

Amyloidosis CardiacAmyloidosis, HereditaryAmyloidosis, Familial+2 more
University of Texas Southwestern Medical Center500 enrolled3 locationsNCT05489549
Recruiting
Not Applicable

Dietary Reporting In The Amyloidoses

Amyloidosis
Barbara Ann Karmanos Cancer Institute40 enrolled1 locationNCT05738005
Recruiting
Phase 2

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

Renal AL Amyloidosis
Barbara Ann Karmanos Cancer Institute20 enrolled1 locationNCT06420167
Recruiting

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

Transthyretin Cardiac Amyloidosis
Idoven 1903 S.L.2,200 enrolled8 locationsNCT06978660
Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca1,850 enrolled74 locationsNCT06465810
Recruiting

The Eplontersen Pregnancy and Lactation Outcomes Study

Transthyretin Amyloidosis
AstraZeneca10 enrolled1 locationNCT07205666
Recruiting
Not Applicable

Evaluation of Skin Tests in Biotherapy Allergies

Colorectal, CancerCholangiocarcinomaEsophageal Squamous Cell Carcinoma+13 more
University Hospital, Angers70 enrolled1 locationNCT06971848
Recruiting
Phase 1Phase 2

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled20 locationsNCT06292780
Recruiting
Phase 1Phase 2

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

AL Amyloidosis
Columbia University53 enrolled6 locationsNCT05451771
Recruiting
Not Applicable

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

Cardiac Amyloidosis
Richmond Research Institute320 enrolled1 locationNCT05098665
Recruiting
Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled233 locationsNCT07052903
Recruiting
Phase 3

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals125 enrolled29 locationsNCT07223203
Recruiting
Not Applicable

Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy

Transthyretin AmyloidosisCarpal Tunnel
Clinique Saint Jean, France500 enrolled1 locationNCT07644325
Recruiting
Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Multiple MyelomaAL Amyloidosis
Shanghai Zhongshan Hospital30 enrolled1 locationNCT07638683